The ocular surface damage associated with the alteration of the tear film causes multiple symptoms, and autologous serum is used as treatment. Objectives: To compare the effect of autologous serum on the ocular surface repair, prepared with two different concentrations (80 y 20 %). Materials and methods: A quasi-experimental prospective study was carried out in 25 patients diagnosed with dry eye through the Schirmer test, tbut and Rose Bengal staining. Autologous serum eye drops wereadministered to 80% in the right eye and 20% in the left eye, and after 30 days of application, tests were once again performed. For the preparation of autologous serum, ethical procedures were performed and the standardized protocol at the University of Lübeck, Germany, was followed according to the Bundesärztekammer guide and the Paul Ehrlich Institute. Results: The application of autologous serum to 80% and 20% showed a significant increase in both tear volume (Schirmer)and tear stability and quality (tbut) and, additionally, ocular surface repair is achieved. No significant differences were found with the two concentrations but with higher concentrations a greater effect on production and time of rupture of the tear film is achieved (p<0.080). Conclusions: The administration of autologous serum as a treatment for dry eye presents repair on the ocular surface in both concentrations of 80% and 20%.

<em><strong>Objectives</strong><em> to determine the quality of ophthalmic drug prescription in terms of relevance, therapeutic group, dosage and correspondence with the list of essentials, known as the Compulsory Health Plan (POs, for its initials in spanish), according to the prescriber’s characteristics in the ophthalmology and optometry services at a hospital in Bogotá. <em><strong>Methodology</strong><em> An observational, descriptive and cross-sectional (prevalence) study was made during 2007-2008, called the “drug utilization research” (DuR). <em><strong>Results</strong><em> It was identified that most ophthalmic prescription drugs are not part of the POs, fitting better in the ophthalmological group. the prescribed medication’s correspondence with the pathology to be solved, which is called indication-prescription pertinence, is higher in ophthalmologist prescriptions. Prescription errors such as “omission in pharmaceutical form”, “dosage and concentration”, “inappropriate medication for diagnosis” and “brand name prescription” are more frequently found in optometrist prescriptions. <em><strong>Conclusions</strong><em> there is a link between the age, gender and profession of the prescriber and the prescribed medication’s quality, which explains the errors in prescription and belonging in the list of essentials.

<em><strong>Objective</strong><em> to identify the ophthalmic use of monoclonal antibodies in hypertensive retinopathy and their effect on visual acuity (VA), vascular angiogenesis and changes in the ocular fundus of hypertensive patients. <em><strong>Materials and methods</strong><em> Literature was reviewed in the Pubmed, Medline, Embasi, Lilacs, The Cochrane Controlled Trials Register, Hinari, Micromedex and Science Direct databases, through the MESH terms <em>monoclonal antibody and hypertensive retinopathy</em>, <em>bevacizumab hypertensive retinopathy, monoclonal antibody therapy hypertensive retinopathy and pegaptanib and hypertensive retinopathy</em>, limited to years 2000 to 2012. Two thousand three hundred and forty-five (2345) studies were found related to the topic, among which those written in English, French, Portuguese and Spanish were selected, as well as those associated with efficacy in the treatment of hypertensive retinopathy and angiogenic changes in diabetic retinopathy. The quality of the scientific evidence was classified through the Oxford methodology. A descriptive analysis of the study variables related to tissue responses was conducted. Monoclonal antibodies are involved in the control of VEGF, which decrease the risk of retinal hemorrhages, reducing retinal thickness. Antibodies such as bevacizumab show 95% effectiveness for improvement in VA (ETDRS 3 Lines D.E. 2.15) while ranibizumab and pegaptanib have 86% in VA improvement (<em>p</em> <0.05). Triamcinolone shows improvement in vascular leakage and macular edema in hypertensive retinopathy associated with diabetes, without any significant differences between groups (<em>p</em>=0.03).